Cohance Lifesciences Share Price: FDA Ka Dhamaka! Profit Gira **87%**, Q3 Results Ne Udaaye Hosh!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Cohance Lifesciences Share Price: FDA Ka Dhamaka! Profit Gira **87%**, Q3 Results Ne Udaaye Hosh!
Overview

Arre yaaron, Cohance Lifesciences (pehle Suven Pharma) ka Q3 FY26 results dekh kar toh hosh ud gaye! Adjusted PAT gira **87.3%** YoY se **₹21.1 Cr** par, aur revenue bhi **19.5%** gir gaya YoY. Sab gadbad hai US FDA ki Warning Letter ki wajah se, jisne Nacham facility mein **₹55 Cr** ke shipments postpone karwa diye. Company ne FY26 ko "transition year" bataya hai.

📉 Numbers Kya Kehte Hain? (The Financial Deep Dive)

Company ka Q3 results dekha toh sach mein figures gir gaye. Adjusted PAT mein 87.3% ki badi girti hui ₹21.1 Cr pe aa gaya, aur revenue bhi 19.5% kam hokar ₹5,445.50 Cr raha. Margins ka toh bura haal ho gaya, EBITDA margins 38.8% se ghaske 15.6% ho gaye. Yeh sab kaafi cost pressures aur operational issues ki wajah se hua.

Nine-month results bhi dekhein toh revenue 6.7% ghat kar ₹16,494.30 Cr hua, aur Adjusted EBITDA 43.4% neeche ₹347.7 Cr pe aa gaya. Adjusted PAT bhi 61.4% kam ho kar ₹151.3 Cr pe aa gaya tha.

🚨 FDA Ki Warning Ne Kiya Dhamal!

Asal masla Nacham facility mein US FDA ki Warning Letter ka hai. Is wajah se company ko temporarily production aur shipments mein dikkat aayi, jiske chalte lagbhag ₹55 Cr ke orders postpone karne pade. Company ab isko theek karne ke liye actions le rahi hai, lekin iska short-term impact toh dikh hi raha hai.

📈 Future Kya Kehta Hai? (Outlook & Strategy)

Management ne FY26 ko ek "transition year" declare kiya hai, jiska matlab hai ki is saal revenue mein early-to-mid double-digit decline hone ki sambhavna hai. Recovery FY27 se start hone ki ummeed hai. Iske peeche ka main reason R&D pipeline projects ka commercial conversion, nayi capacities ko operationalise karna aur unhe scale up karna hai. Special focus Antibody-Drug Conjugates (ADC) aur Oligonucleotides pe hai. US mein ADC supply ke liye $10 million ka expansion FY27 tak chal raha hai.

🏦 Financial Health Aur Deals

Company ki financial position abhi bhi mazboot hai. Unke paas ₹175.9 Cr ki net cash positive position hai. 9MFY26 mein ₹175 Cr ka free cash flow bhi generate kiya. Borrowings ko bhi kam kar ke ₹256 Cr pe laa diya hai. Recent mein mergers jaise Casper Pharma ke saath aur 56% stake NJ Bio Inc. mein kharidna strategy ka hissa hai.

🚩 Risks Aur Aage Ki Raah

Investors ko sabse pehle US FDA Warning Letter ka resolution dekhna hoga. Agar yeh jaldi theek nahi hua toh future shipments aur revenue par aur asar pad sakta hai. Specialty Chemicals mein regulatory delays bhi ek chinta ka vishay hai. Dekhte hain company FY27 mein apni recovery strategy ko kitna successful bana paati hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.